Pluristem Therapeutics Inc. (NASDAQ:PSTI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.

According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “

Several other research analysts also recently commented on PSTI. Maxim Group reaffirmed a “buy” rating on shares of Pluristem Therapeutics in a research note on Wednesday, July 27th. HC Wainwright reaffirmed a “buy” rating and issued a $3.50 price objective on shares of Pluristem Therapeutics in a research note on Thursday, August 4th.

Shares of Pluristem Therapeutics (NASDAQ:PSTI) opened at 1.51 on Tuesday. The firm has a 50-day moving average price of $1.53 and a 200 day moving average price of $1.53. The stock’s market cap is $122.34 million. Pluristem Therapeutics has a 52 week low of $0.71 and a 52 week high of $1.85.

A hedge fund recently raised its stake in Pluristem Therapeutics stock. Jane Street Group LLC increased its position in Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 33.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 104,754 shares of the company’s stock after buying an additional 26,038 shares during the period. Jane Street Group LLC owned about 0.13% of Pluristem Therapeutics worth $139,000 as of its most recent filing with the SEC. 3.75% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Pluristem Therapeutics Inc. (PSTI) Stock Rating Lowered by Zacks Investment Research” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/24/pluristem-therapeutics-inc-psti-stock-rating-lowered-by-zacks-investment-research.html.

About Pluristem Therapeutics

Pluristem Therapeutics Inc (Pluristem) is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company focuses on cardiovascular, orthopedic, pulmonary, hematological and women’s health diseases. The Company is focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies.

5 Day Chart for NASDAQ:PSTI

Receive News & Stock Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related stocks with our FREE daily email newsletter.